ArticlePloS one2025
Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Behavioural Drivers of COVID-19 Vaccination and Antiviral Uptake in Australia: A Cross-Sectional Analysis Using the COM-B Framework.Vaccines · 2026Article
- Knowledge and Preventive Practices Toward COVID-19 Among Sex Workers in Chiang Mai, Thailand.International journal of environmental research and public health · 2025Article
- Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults.Infectious diseases and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about public perceptions of antivirals for the treatment of mild-to-moderate COVID-19 in the United States (US). Our objective was to explore adult perceptions toward COVID-19 antivirals to improve outreach communications about antivirals for COVID-19.
methodsDuring July 2022, potential respondents ≥18 years were randomly sampled from a national opt-in internet panel, with oversampling of African Americans, Hispanics, and adults ≥65 years. Respondents were asked about sociodemographic factors, and knowledge, attitudes, and perceptions regarding COVID-19 antivirals. Results were weighted to represent the non-institutionalized US adult population.
resultsAmong 1,155 respondents, 51% were female, 21% were 50-64 years, and 19% were ≥65 years. Compared to younger age groups, a greater proportion of adults ≥65 years were knowledgeable about COVID-19 antivirals and would take them if they tested positive or their doctor recommended them. Adults ≥65 years and those reporting immunosuppression or disability had the highest rates of willingness to take antivirals. For all groups, the proportion of people willing to take antivirals increased by >20% if recommended by their doctor. Respondents in the 50-64 and ≥65 groups who were sure they would take COVID-19 antivirals were more likely to be fully vaccinated and less likely to be living in isolation.
conclusionGroups that are less likely to have been vaccinated, those living in isolation, and those not sure about whether they would take an antiviral or not may be at risk for not receiving treatment to prevent severe COVID-19 outcomes. However, trust in doctor recommendations may be enough to overcome individual patient concerns about COVID-19 antivirals. Targeted initiatives to educate those at risk for severe COVID-19 outcomes about the effectiveness of antivirals may be needed to further lower this population's risk of severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.